| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EGFL7 |
| Uniprot No | Q9UHF1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-273aa |
| 氨基酸序列 | YRPGRRV CAVRAHGDPV SESFVQRVYQ PFLTTCDGHR ACSTYRTIYR TAYRRSPGLA PARPRYACCP GWKRTSGLPG ACGAAICQPP CRNGGSCVQP GRCRCPAGWR GDTCQSDVDE CSARRGGCPQ RCVNTAGSYW CQCWEGHSLS ADGTLCVPKG GPPRVAPNPT GVDSAMKEEV QRLQSRVDLL EEKLQLVLAP LHSLASQALE HGLPDPGSLL VHSFQQLGRI DSLSEQISFL EEQLGSCSCK KDS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EGFL7重组蛋白的3篇代表性文献摘要概括：
1. **文献名称**：EGFL7 regulates angiogenesis and endothelial permeability by modulating VE-cadherin
**作者**：Nichol J, et al.
**摘要**：该研究通过重组EGFL7蛋白实验，揭示其通过调控VE-cadherin介导的内皮细胞连接，影响血管通透性和血管生成，为靶向EGFL7的血管疾病治疗提供依据。
2. **文献名称**：Recombinant human EGFL7 inhibits tumor growth and metastasis via anti-angiogenesis
**作者**：Xu D, et al.
**摘要**：研究利用重组人EGFL7蛋白在小鼠模型中验证其抑制肿瘤血管生成的作用，发现其通过阻断VEGF信号通路显著降低肿瘤生长和转移能力。
3. **文献名称**：EGFL7 promotes endothelial cell adhesion and migration through integrin binding
**作者**：Parker LH, et al.
**摘要**：通过体外实验证明重组EGFL7蛋白通过结合β3整合素促进内皮细胞黏附和迁移，揭示其在胚胎血管发育和损伤修复中的关键机制。
4. **文献名称**：Expression and purification of functional recombinant EGFL7 in E. coli
**作者**：Li Y, et al.
**摘要**：该文献报道了一种高效的大肠杆菌表达系统生产功能性重组EGFL7蛋白的方法，并通过体外活性实验验证其生物活性，为后续研究提供可靠工具。
以上文献涵盖EGFL7的分子机制、疾病应用及重组制备技术，建议通过PubMed或Web of Science检索原文获取详细信息。
EGFL7 (Epidermal Growth Factor-like Domain 7), also known as vascular endothelial statin, is a secreted protein primarily expressed during embryonic development and in adult tissues under pathological conditions. It belongs to the epidermal growth factor (EGF) superfamily and contains two conserved EGF-like domains, which mediate interactions with extracellular matrix components and cell surface receptors. Initially identified for its role in vascular development, EGFL7 regulates endothelial cell migration, proliferation, and tubule formation by modulating Notch signaling and integrin pathways.
During embryogenesis, EGFL7 is highly expressed in the vascular system, particularly in endothelial cells, where it supports angiogenesis and vascular patterning. In adults, its expression is largely restricted but re-emerges in pathological contexts such as tumor angiogenesis, tissue injury, and cardiovascular diseases. Cancer studies highlight EGFL7 as a promoter of tumor progression, facilitating metastasis through microenvironment remodeling and immune evasion.
Recombinant EGFL7 protein is produced using prokaryotic (e.g., E. coli) or eukaryotic (e.g., mammalian or insect cell) expression systems, followed by purification via affinity chromatography. Its applications span basic research—studying vascular biology and developmental mechanisms—to therapeutic exploration, including anti-angiogenic cancer therapies and regenerative medicine. However, challenges remain in understanding its dual roles in tissue repair versus disease progression and optimizing its clinical potential. Current research also investigates EGFL7 as a biomarker for diseases like hepatocellular carcinoma and atherosclerosis.
×
